<DOC>
	<DOCNO>NCT00371735</DOCNO>
	<brief_summary>CDA combination chlorproguanil , dapsone artesunate , develop public-private partnership Medicines Malaria Venture ( MMV ) , World Health Organisation ( WHO-TDR ) academic partner London School Hygiene Tropical Medicine , University Liverpool Liverpool School Tropical Medicine treatment acute uncomplicated P. falciparum malaria . The combination chlorproguanil HCl ( CPG ) dapsone ( DDS ) chlorproguanil-dapsone already show efficacious P.falciparum adult child Sub-Sahara Africa . The addition artesunate LAPDAP demonstrate increase parasite kill rate demonstrate phase II study , reduce chance parasite escape treatment 3-day course . The addition artesunate also anticipate population benefit protection development resistant strain P.falciparum , although possible demonstrate clinical trial . One population benefit artemisinin drug ability suppress sexual form parasite ( gametocyte ) , reduce infectivity antimalarial treatment potentially low transmission rate widespread use , include spread parasite resistant partner drug . The aims phase III study compare efficacy fix ratio combination tablet CDA chlorproguanil-dapsone , collect support safety data . This multi-centre , double-blind , double-dummy , randomised trial , child , adolescent adult , chlorproguanil-dapsone comparator .</brief_summary>
	<brief_title>Chlorproguanil-Dapsone-Artesunate ( CDA ) Versus Chlorproguanil-Dapsone ( LAPDAP ) For Uncomplicated Malaria</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Chlorproguanil</mesh_term>
	<mesh_term>Proguanil</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>Inclusion criterion : Acute , uncomplicated P.falciparum malaria , microscopically confirm infection . Temperature screen 37.5oC confirmed history fever within previous 24hours . Weight 7.5kg , upper weight limit . Screening haemoglobin ( Hb ) 7g/dl , haematocrit 25 % ( Hb available screening ) . Willingness comply study visit procedure , outline informed consent form . Written oral witness consent obtain subject , parent guardian . Assent give child age 12 &lt; 18years , addition consent parent guardian . Exclusion criterion : Features severe/complicated falciparum malaria . Hypersensitivity active substance ( chlorproguanil , dapsone , artesunate ) , excipients investigational product . Known allergy biguanides , sulphones , sulphonamides artemisinin derive product . Known history G6PD deficiency . Infants history hyperbilirubinaemia neonatal period . Evidence concomitant infection time presentation ( include P. vivax , P. ovale P. malariae ) . Use concomitant medication may induce haemolysis haemolytic anaemia WHO ( World Health Organization ) list essential drug . Any underlying disease may compromise diagnosis evaluation response study medication ( include clinical symptom immunosuppression , tuberculosis , bacterial infection ; cardiac pulmonary disease ) . Malnutrition , define child whose weightforheight 3 standard deviation less 70 % median NCHS/WHO normalise reference value Treatment within past three month mefloquine mefloquinesulphadoxinepyrimethamine ; twentyeight day sulphadoxine/pyrimethamine , sulfalene/pyrimethamine , lumefantrine artemether/lumefantrine , amodiaquine , atovaquone atovaquone/proguanil , halofantrine ; 14days chlorproguanil/dapsone , 7days quinine ( full course ) , proguanil , artemisinin , tetracycline doxycycline clindamycin . Positive sulphadoxine/pyrimethamine urine screen 'unknown ' antimalarial drug use prior 28days . Use investigational drug within 30 day 5 halflives whichever longer . Previous participation study . Female subject childbearing potential positive pregnancy test enrolment , give consent take pregnancy test . Female subject breastfeed infant duration study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Malaria CDA LAPDAP Africa</keyword>
</DOC>